

IN THE CLAIMS

Claim 1. [Currently Amended] A purified mammalian dihydroouabain-like factor (Dh-OLF) having binding reactivity with antibody raised against plant-related dihydroouabain (dho). *bovine*

Claim 2. [Currently Amended] The factor of claim 1 having the same [a] high pressure liquid chromatography elution pattern as dho-B [similar to dho].

Claim 3. [Currently Amended] The factor of claim 1 [lacking substantial] having less than about 2-3% binding reactivity with the antibody raised to plant-derived ouabain or mammalian ouabain-like sodium pump inhibitory factor (OLF).

Claim 4. [Original] The factor of claim 1 having 10-fold lower potency than OLF and 3-fold higher potency than dho for inhibiting sodium pump activity.

Claim 5. [Original] The factor of claim 1 which is of human origin.

Claim 6. [Original] The factor of claim 1 which is of bovine origin.

Claim 7. [Original] The factor of claim 1 which is obtained by reduction of OLF.

*Ex. Note* Claim 8. *[Original]* A pharmaceutical composition comprising the mammalian Dh-OLF factor of claim 1 and a pharmaceutically or veterinarily acceptable carrier. *bovine*

Claim 9. [Original] The composition of claim 8 in the form of a formulation selected from the group consisting of oral, parenteral, ophthalmic, slow release and enteric coating formulations.

Claims 10-34. [withdrawn]